$MNKD Company News Skullcandy gains on upgrade,Tesla

New Post Public Reply Private Reply Replies (0) Message Board

Oct 5, 2014 at 12:47 PM

$MNKD Company News

Skullcandy gains on upgrade,Tesla reverses gains 2:37 p.m. Aug. 12, 2014 - Sue Chang
U.S. small caps lead broad stock-market gains 4:09 p.m. Aug. 11, 2014 - Anora Mahmudova
Kinder Morgan soars, Tesla rallies on upgrade 12:46 p.m. Aug. 11, 2014 - Sue Chang
MannKind shares soar on Sanofi deal; investors ignore earnings report 10:10 a.m. Aug. 11, 2014 - Russ Britt
Super-Moon illusion or buy the dips on this stock market? 7:52 a.m. Aug. 11, 2014 - Barbara Kollmeyer
MannKind shares soar 23% on Sanofi deal over Afrezza 7:04 a.m. Aug. 11, 2014 - Silvia Ascarelli
Sanofi, MannKind to commercialize Afrezza insulin therapy 5:32 a.m. Aug. 11, 2014 - Silvia Ascarelli
Puma Biotech’s blast-off is not a typical short squeeze 12:10 p.m. July 23, 2014 - Tomi Kilgore
S&P 500 posts strongest 2nd quarter since 2009: Stock market live blog recap 3:33 p.m. June 30, 2014 - blogs.marketwatch.com
MannKind, GoPro rise; Yahoo gains on upgrade 12:02 p.m. June 30, 2014 - Sue Chang
MannKind shares up 23.1% in premarket trade 7:19 a.m. June 30, 2014 - Ciara Linnane
Six more bull months ahead, and GoPro keeps on going 6:28 a.m. June 30, 2014 - Sara Sjolin
MannKind wins approval for its inhaled insulin — and its stock drops? 4:30 p.m. June 27, 2014 - Russ Britt
DuPont falls on outlook; Michaels debuts 4:08 p.m. June 27, 2014 - Sue Chang
3 overlooked stocks loved by top-ranked advisers 3:09 p.m. April 25, 2014 - Mark Hulbert
Tesla, Facebook seesaw; Questcor surges on deal 3:54 p.m. April 7, 2014 - Sue Chang
MannKind drops after FDA says its review on drug will last until July 1:46 p.m. April 7, 2014 - Russ Britt
Stock futures drop as earnings season looms 9:20 a.m. April 7, 2014 - Sara Sjolin
MannKind drops 12% after FDA review extension 7:15 a.m. April 7, 2014 - Ben Eisen
MannKind drops 16% after FDA review extension 7:01 a.m. April 7, 2014 - Ben Eisen

MannKind Receives $150 Million Upfront Payment from Sanofi - Analyst Blog 5:10 p.m. Oct. 3, 2014 - Zacks.com
MannKind Reality Check 10:23 a.m. Oct. 2, 2014 - Seeking Alpha
Why MannKind Stock (MNKD) Is a Screaming Buy 10:16 a.m. Oct. 2, 2014 - InvestorPlace.com
With Ebola Looming, When Will The Defense Department Get Around To Generex? 3:22 a.m. Oct. 1, 2014 - Seeking Alpha
5 Stocks With Awful Sales Growth — HTS MITT UEC MNKD CTEL 4:15 a.m. Sept. 29, 2014 - InvestorPlace.com
MannKind and Sanofi Complete Afrezza Collaboration Deal - Analyst Blog 4:45 p.m. Sept. 26, 2014 - Zacks.com
Sanofi Vs. MannKind - Afrezza Is Better For Sanofi 12:56 p.m. Sept. 26, 2014 - Seeking Alpha
NASDAQ Dips 1.5%; HB Fuller Shares Decline On Downbeat Results 11:09 a.m. Sept. 25, 2014 - benzinga.com
Markets Tumble; Scholastic Posts Wider Fiscal-First Quarter Loss 10:12 a.m. Sept. 25, 2014 - benzinga.com
Short Sellers Make Moves in Key Biotech Stocks 9:54 a.m. Sept. 25, 2014 - 247WallSt.com
Hottest Healthcare Stocks Now – MNKD PTCT VRX CLDX 8:00 a.m. Sept. 25, 2014 - InvestorPlace.com
Cramer's Mad Money - 2 Stocks To Buy Starting With 'A' (9/23/14) 5:49 a.m. Sept. 24, 2014 - Seeking Alpha
5 Stocks With Ugly Sales Growth — HTS MITT UEC MNKD CTEL 3:45 a.m. Sept. 22, 2014 - InvestorPlace.com
Why You Shouldn't Bet Against MannKind (MNKD) Stock - Tale of the Tape 8:39 a.m. Sept. 18, 2014 - Zacks.com
MannKind: Seeing The Forest Through The Trees 6:37 p.m. Sept. 16, 2014 - Seeking Alpha
Al Mann Trounces The Afrezza Bear Case In Interview With Noted Diabetes Educator 6:01 p.m. Sept. 16, 2014 - Seeking Alpha
5 Stocks With Awful Sales Growth — HTS MITT UEC MNKD CTEL 4:45 a.m. Sept. 15, 2014 - InvestorPlace.com
New Diabetes Drugs Gain Approval - Florins Versus Oral Insulin 2:15 p.m. Sept. 14, 2014 - Seeking Alpha
MannKind In Turmoil: Is It Time To Buy Or Sell? 7:52 a.m. Sept. 12, 2014 - Seeking Alpha
MannKind: Nothing But Good News, Trading Volume Drops, Short Interest Remains Sky High 3:30 p.m. Sept. 11, 2014 - Seeking Alpha

Critical Alerts For MannKind, Sarepta Therapeutics, Noodles & Company, VoxelJet and Lululemon Released By InvestorsObserver 9:31 a.m. Oct. 3, 2014 - PR Newswire - PRF
Insider Trading Alerts for Comcast, RF Micro Devices, Broadcom, GoPro, MannKind, and Yahoo 8:55 a.m. Oct. 3, 2014 - PR Newswire - PRF
MannKind Announces Receipt of $150 Million Licensing Upfront Payment 7:30 p.m. Sept. 29, 2014 - GlobeNewswire
Insider Trading Reports for Apple, Cisco, Yahoo, Tesla, MannKind, and Bank of America 8:30 a.m. Sept. 29, 2014 - PR Newswire - PRF
Insider Trading Alerts for Facebook, Apple, Cisco, Verizon, MannKind, and Tesla Motors 8:55 a.m. Sept. 26, 2014 - PR Newswire - PRF
MannKind Announces Closing of Global Licensing Agreement With Sanofi 5:01 p.m. Sept. 24, 2014 - GlobeNewswire
Critical Alerts For Intel, Zynga, Isis Pharmaceuticals, Arrowhead Research and MannKind Released By InvestorsObserver 9:31 a.m. Sept. 16, 2014 - PR Newswire - PRF
Technical Coverage on Biotech Equities - Galena Biopharma, Gilead Sciences, MannKind, Orexigen Therapeutics, and IsoRay 9:05 a.m. Sept. 3, 2014 - PR Newswire - PRF
MannKind Corporation to Present at Morgan Stanley Global Healthcare Conference 5:01 p.m. Sept. 2, 2014 - GlobeNewswire
Critical Alerts For MannKind, Best Buy, Splunk, Rite Aid and Allscripts Released By InvestorsObserver 9:31 a.m. Aug. 28, 2014 - PR Newswire - PRF
Drug Approvals & Updates, Licensing Agreements, and Upcoming Conferences - Research Reports on Tekmira, MannKind, Eli Lilly, GSK and Cigna 8:30 a.m. Aug. 14, 2014 - PR Newswire - PRF
Critical Alerts For MannKind, Kinder Morgan, Kohls, Maxim Integrated Products and United Technologies. Released By InvestorsObserver 9:31 a.m. Aug. 12, 2014 - PR Newswire - PRF
MannKind Corporation Reports 2014 Second Quarter Financial Results 9:01 a.m. Aug. 11, 2014 - GlobeNewswire
Sanofi and MannKind Announce Global Licensing Agreement for Afrezza® (insulin human) Rapid-Acting Inhaled Insulin 7:00 a.m. Aug. 11, 2014 - PR Newswire - PRF
Sanofi and MannKind Announce Global Licensing Agreement for Afrezza(R) (insulin human) Rapid-Acting Inhaled Insulin 1:13 a.m. Aug. 11, 2014 - GlobeNewswire
MannKind Corporation to Hold 2014 Second Quarter Financial Results Conference Call on August 11, 2014 5:00 p.m. Aug. 5, 2014 - GlobeNewswire
Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma 9:00 a.m. Aug. 1, 2014 - PR Newswire - PRF
Critical Alerts For MannKind, CVS Caremark, Express Scripts, Cheniere Energy, and HomeAway Released By InvestorsObserver 9:31 a.m. July 21, 2014 - PR Newswire - PRF
NDA Submission, Results Release Schedules, FDA Grants and Approvals, and Agreements - Analyst Notes on Gilead, Biogen Idec, Amgen, Illumina and MannKind 5:20 a.m. July 4, 2014 - PR Newswire - PRF
MannKind Corp Analyst Report; Afrezza is Approved and Future Developments by BrokerBank Securities, Inc. 11:15 a.m. July 3, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aetna's 2027 Medicare Plans: Comprehensive Outlook

Unpacking Aetna's Medicare Strategy for 2027 Look, if there's one thing you should keep tabs on, it's how Aetna isn't just coasting by in the healthcare arena. These folks are pushing forward with new options for 2027 that prove they're serious about making healthcare not just accessible, but affordable across the board. Aetna, backed by CVS Health (NYSE: CVS), is making...

Ractigen's Breakthrough in DMD: RNA Activates Utrophin

Ractigen's New Fight Against Duchenne: A Personal Take When it comes to biotech advancements, I've seen enough breakthroughs to not get swayed easily. But Ractigen Therapeutics presenting their first-in-human data on RNA activation for Duchenne Muscular Dystrophy (DMD) kind of demands your attention. Folks, they're talking about a potential shift in handling this brutal...

Venice's Climate Challenge: Rising Seas, Sinking Lands

Sea Rise Isn’t Just a Statistics Problem The ordeal of rising seas isn't just about staring at numbers in some spreadsheet, it's a real-world gut punch that's knocking at Venice's door. This city, known for its stunning architecture and winding canals, now serves as the poster child for what happens when Mother Nature and human errors leave a place on the brink of...

The Real Cost of Cabinet Decisions: Refinish or Replace?

Uncovering the Truth Behind Cabinet Decisions When it comes to sprucing up a kitchen, most folks overlook what's hanging on their walls already: those tired old cabinets. Now, are you looking at chucking them out the window for brand-new ones, or can a fresh coat of paint breathe new life into them? Well, that's where Melvin Jones, a painting virtuoso from Lexington,...

Vatrer Power: Lithium Batteries Revolutionize Golf Carts

The humdrum world of golf carts just got a jolt of energy with lithium batteries entering the fray. Vatrer Power, the brain behind some nifty LiFePO4 lithium battery conversions, made some noise at this year's Golf Carting Expo & Dealer Summit in Charleston, South Carolina. Held at the North Charleston Convention Center, this trade show was the industry's premier...

Kal Plastics Showcases at Design-2-Part Expo

Kal Plastics Steps into the Limelight There's a buzz in the air, and it's all about Kal Plastics getting ready to strut their stuff at the Southern California Design-2-Part Show. Now, most folks probably don't spend their nights dreaming about thermoforming and pressure forming, but these guys sure make a case for it. They’ve got their eyes on impressing the crowd with...

Trading Platforms Poised for Billions by 2031

Forecasts and Fierce Digital Landscapes Just when you thought the online trading realm was getting saturated, the numbers are making it clear: there’s still room for growth—even explosive growth. The online trading platform market is eyeing a hike, jumping from a $11.65 billion valuation in 2025 to a projected $18.18 billion by 2031, according to Mordor Intelligence....

Govee Stirs Halloween Chills with New Sarah Gellar Ad

Lighting Up Halloween the Hollywood Way When it comes to Halloween, folks go nuts driving up the thrill factor at home, and boy, has Govee nailed it this time around. They've dragged Sarah Michelle Gellar into their spooky mix, transforming homes into eerie masterpieces. And let's face it, who better than the 'Buffy the Vampire Slayer' herself to stir those spine-tingling...

Honeywell's Supply Line Snags Bait Class Action Risk

Stepping into the chaos of the stock market sometimes feels like opening Pandora's box—just when you think you've seen it all, something new tumbles out. This time around, it's Honeywell Aerospace (NasdaqGS: HONA) playing catch with hot coals, and a burning class-action lawsuit smolders in the air. Deadline Looms for Investors in Class Action Heads up, folks! If you've...